Changhua Mu

Has grant

Assistant Professional Researcher

University of California, San Francisco
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Recent Grants

Grant: Close

Preparation of Hyperpolarized Carbona-13 pH Imaging Methods for Clinical Translation in Prostate Cancer

Open Date: 2022-02-01

Close Date: 2023-02-01

Grant: Close

Development of a Method to Image Zinc Distribution Using Positron Emission Tomography and Initial Application in Prostate Cancer Models

Open Date: 2020-07-01

Close Date: 2021-07-01

Articles (29)

Year:

2026

The enhanced permeability and retention (EPR) effect controls passive nanodrug uptake in tumors and may provide a high tumor payload with prolonged retention for cancer treatment. However, EPR-mediated tumor uptake and distribution vary by cancer phenotype. Thus, we hypothesized that a companion PET imaging surrogate may benefit EPR-mediated therapeutic drug delivery. We developed two 89Zr-radiolabeled nanocarriers based on 4-armed starPEG40kDa with or without talazoparib (TLZ), a potent PARP inhibitor, as surrogates for the PEG-TLZ4 therapeutic scaffold. For PET imaging, PEG-DFB4 and PEG-DFB1-TLZ3 were radiolabeled with 89Zr by replacing one or all four copis of TLZ on PEG-TLZ4 with deferoxamine B (DFB). The radiolabeled nanodrugs [89Zr]PEG-DFB4 and [89Zr]PEG-DFB1-TLZ3 were tested in vivo in prostate cancer subcutaneous (s.c.) xenografts (22Rv1, LTL-545, and LTL-610) and 22Rv1 metastatic models. Their EPR-mediated tumoral uptake and penetration was compared with CT26, a known EPR-high cell line. MicroPET/CT images, organ biodistribution, and calculated kinetic parameters showed high uptake in CT26 and LTL-545 and moderate to low uptake in LTL-610 and 22Rv1. MicroPET/CT and high-resolution autoradiographic images showed nanocarrier penetration into highly permeable CT26, but heterogeneous peripheral accumulation was observed in LTL-545, LTL-610, and 22Rv1 s.c. xenografts and metastatic tumors. CD31 staining of tumor sections showed homogenous vascular development in CT26 tumors and heterogeneity in other xenografts. Both [89Zr]PEG-DFB4 and [89Zr]PEG-DFB1-TLZ3 showed similar accumulation and distribution in s.c. and metastatic tumor models. Both nanocarriers can measure tumor model passive uptake heterogeneity. Although heterogeneous, prostate cancer xenografts had low EPR. These starPEG nanocarriers could be used as PET imaging surrogates to predict drug delivery and efficacy.

Year:

2025

Supplementary Table S15. Organ biodistribution analysis data in %ID/g tissue for 89Zr labeled nanocarriers at 96 h in metastatic mice model with 22rv1 cell inoculated in kidney capsule tumors. (n = 4)

Year:

2025

Supplementary Figure S7. Coronal μPET/CT fusion and MIP images obtained at 24 h, 48 h, 72 h, and 96 h following administration of 150-170 μCi of 89Zr labeled nanocarriers in nude mice bearing LTL-610 patient derived xenograft (PDX) of tumors over left flanks.

Year:

2025

Supplementary Figure S6. Coronal μPET/CT fusion and MIP images obtained at 24 h, 48 h, 72 h, and 96 h following administration of 150-170 μCi of 89Zr labeled nanocarriers in nude mice bearing LTL-545 patient derived xenograft (PDX) of tumors over left flanks.

Year:

2025

Supplementary Figure S3. Ex vivo tumor biodistribution, (a) %ID per gram and (b) %ID per organ of nude mice bearing different tumor models including prostate cancer (22rv1, PC3, DU145), colorectal cancer (CT26), and pancreatic cancer (BxPC3) at 24h and 72 h post-injection of [89Zr]PEG-DFB1-TLZ3. The respective (c) tumor uptakes, (d) tumor to muscle ratio, and (e) tumor to blood ratio of the same mice. (n = 4, mean ± SD) (f) Autoradiographic images of tumor sections from mouse model bearing different preclinical cancer xenograft at 72h post-injection of [89Zr]PEG-DFB1-TLZ3.

Year:

2025

Supplementary Figure S19. Coronal μPET/CT fusion and MIP images obtained at 24 h, 48 h, 72 h, and 96 h following administration of 150-170 μCi of [89Zr]PEG-DFB1-TLZ3 in nude mice inoculated with 22rv1 cells in the left kidney capsule (red arrow). Yellow arrows indicate metastatic tumor.

Year:

2025

Supplementary Figure S1. (a) Zeta potential of the StarPEG conjugates PEG-DFB4 and PEG-DFB1-TLZ3 with an average surface charge of -4.04±0.21 mV and -1.41±0.22 mV, respectively (n = 3). (b) TEM images of PEG-DFB4 and PEG-DFB1-TLZ3 showing the formation of nanoparticles in the range of 10 to 15 nm. TEM samples were prepared by dropcasting the water solution (0.25 mg/mL) of respective StarPEG on carbon coated copper grid of 200 mesh.

Year:

2025

Supplementary Table S14. Comparison of influx and efflux rates of [89Zr]PEG-DFB4 and [89Zr]PEG-DFB1-TLZ3 conjugates in different subcutaneous tumor models (n = 4, mean ± SD). *Prior published data.6

Year:

2025

Supplementary Figure S22. BLI of all mice in the cohort inoculated with 22rv1-Luc cells in the left kidney capsule that demonstrate prominent signal of metastatic tumors at the neck and thigh region on the day of 89Zr labeled nanocarrier injection.

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2023

Collaborators (11)

Henry VanBrocklin

Professor/ Director of Radiopharmaceutical Research

University of California, San Francisco

UNITED STATES
View details

David M. Wilson

University of California

UNITED STATES
View details

Renuka Sriram

University of California

UNITED STATES
View details

Anil Parsram Bidkar

Assistant Professional Researcher

University of California, San Francisco

UNITED STATES
View details

Jonathan Chou

Assistant Professor

University of California, San Francisco

UNITED STATES
View details

Robert R. Flavell

University of California

UNITED STATES
View details

Y. Seo

University of California, San Francisco

UNITED STATES
View details

Rahul Aggarwal

University of California

UNITED STATES
View details

Megha Basak

University of California, San Francisco

UNITED STATES
View details

kondapa Naidu Bobba

Assistant professor

University of Tennessee

UNITED STATES
View details

Sunita P. Ho

Professor

University of California, San Francisco

UNITED STATES
View details